Author:
Mitoma Tomohiro,Maki Jota,Ooba Hikaru,Eto Eriko,Takahashi Kasumi,Kondo Tsunemasa,Ikeda Tomohiro,Sakamoto Yoko,Mitsuhashi Toshiharu,Masuyama Hisashi
Abstract
Abstract
Background
Knee osteoarthritis (KOA) is highly prevalent in older women, and previous studies suggest the involvement of hormonal factors play a role in the pathogenesis of osteoarthritis. KOA causes musculoskeletal impairment, resulting in decreased physical activity, muscle mass, and strength, which leads to sarcopenia and further increases the burden on healthcare systems. Oestrogen replacement therapy (ERT) improves joint pain and muscle performance in early menopausal women. Muscle resistance exercise (MRE) is a non-pharmacological method that preserves the physical functions of patients with KOA. However, data on short-term oestrogen administration combined with MRE in postmenopausal women, especially in those aged > 65 years, are limited. Therefore, this study presents a protocol of a trial aimed to examine the synergistic effect of ERT and MRE on lower-limb physical performance in older women with KOA.
Methods
We will conduct a double-blinded, randomised placebo-controlled trial in 80 Japanese women aged > 65 years living independently with knee pain. The participants will be randomly categorised into two groups: (1) 12-week MRE programme with transdermal oestrogen gel containing 0.54 mg oestradiol per push and (2) 12-week MRE programme with placebo gel. The primary outcome measured using the 30-s chair stand test, and secondary outcomes (body composition, lower-limb muscle strength, physical performance, self-reported measure of knee pain, and quality of life) will be measured at baseline, 3 months, and 12 months, and these outcomes will be analysed based on the intention-to-treat.
Discussion
The EPOK trial is the first study to focus on the efficacy of ERT on MRE among women aged > 65 years with KOA. This trial will provide an effective MRE to prevent KOA-induced lower-limb muscle weakness, confirming the benefit of short-term oestrogen administration.
Trial registration
Japan Registry of Clinical Trials: jRCTs061210062. Registered 17th December 2021,
https://jrct.niph.go.jp/en-latest-detail/jRCTs061210062.
Funder
Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Subject
Geriatrics and Gerontology
Reference71 articles.
1. Arai H, Ouchi Y, Toba K, Endo T, Shimokado K, Tsubota K, Matsuo S, Mori H, Yumura W, Yokode M, Rakugi H, Ohshima S. Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan. Geriatr Gerontol Int. 2015;15(6):673–87.
2. Stiefel MC, Perla RJ, Zell BL. A healthy bottom line: healthy life expectancy as an outcome measure for health improvement efforts. Milbank Q. 2010. https://doi.org/10.1111/j.1468-0009.2010.00588.x.
3. Cabinet Office Japan. Annual Report on the Ageing Society [Summary] FY2021. In: Policy on the Ageing Society. Cabinet Office Japan. 2022. https://www8.cao.go.jp/kourei/english/annualreport/2021/pdf/2021.pdf. Accessed 24 June 2022.
4. Long H, Liu Q, Yin H, Wang K, Diao N, Zhang Y, Lin J, Guo A. Prevalence Trends of Site-Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study 2019. Arthritis Rheumatol. 2022;74(7):1172–83.
5. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858.